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Abstract
Objective: To determine the safety and efficacy of vaccinating the male gender to prevent HPV
related neoplastic disorders in both the male and female genders.

Study Design: Review of all randomized controlled trials and comparative studies in the
English language from the time periods of 2000 to 2009.

Data Sources: Two RCT’s and one comparative study was found using PubMed, Ovid,
Cochrane database of Randomized Control Trials, and Cochrane database of Systematic
Reviews.

Outcomes Measured: Outcomes were measured for safety and efficacy. Outcomes were based
upon a vaccination report card (VRC) and proven immunity to the HPV types being studied.
Participants were given a scale and asked to rate their symptoms based upon mild, moderate, or
severe. “Mild” was defined as awareness of signs or symptoms, but easily tolerated; “moderate”
was defined by discomfort enough to cause interference with usual activities; and “severe” was
incapacitating with the inability to work or do usual activities (Block).1 Titer levels were drawn
to associate immunogenicity within the participants. Numeric values of titer levels however are
not POEM based. What is POEM based is whether or not these patients will be able to know
that they are protected from contracting or transmitting HPV 6/11/16/18 and related neoplasm’s.
Results: Two RCT’s and one comparative study were included in this review. All three of the
studies proved safety and efficacy of either the quadrivalent or bivalent HPV vaccine. Very few
serious adverse events (SAEs) were contributed to the vaccination. Only 1 SAE was said to be
vaccination related. Immunogenicity was proved to be non-inferior to girls and women in all 3
studies.

Conclusions: The Block study, the Petaja study, and the Reisinger study all show that the HPV
vaccine is overall safe and effective for the male population.
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Introduction
Human Papillomavirus (HPV) infections are responsible for causing neoplasms in both
the male and female genders. There are more than 100 HPV viruses, and around 30 out of these
100 are passed through sexual contact. HPV infections are divided into two groups; low risk and
high risk.

The low risk types are known to be HPV types 6 and 11; the high risk types are

known to be HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73. The high risk
category is known to be oncogenic or carcinogenic. HPV infections are common with a lifetime
risk exceeding 50% for both males and females.3 HPV is a major cause of cervical and
anogenital cancers; therefore the high prevalence of genital HPV infection is considered a
serious worldwide health issue.3 Due to the well-established link between HPV and anogenital
cancers, genital warts, and low/high grade dysplasia, there is now a prophylactic vaccine
available for the four most common types of low and high risk HPV. The quadrivalent vaccine
was approved in 2006 and first available only to females; this vaccine is now extended to males
after FDA approval in October 2009.6
Worldwide, greater than 500,000 cases of cervical and other genital cancers are caused
by HPV infection annually, with greater than 273,000 deaths attributable to cervical cancer.1
Studies have shown that the first 5 years following sexual debut represents the period of highest
risk for acquisition of HPV infection.3 An estimated annual cost for HPV related neoplasms in
the year 2000 for ages 15-24 was $2.8 billion for women, and $62 million for men.5 In most
countries the median/mean age of a primary sexual experience occurs between 15 and 16 years
of age.3 Studies have also proved that oral HPV infection is a strong risk factor for
oropharyngeal cancer. Researchers found that an oral HPV infection and past HPV exposure
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increase the risk of oropharyngeal of squamous cell cancer regardless of tobacco and alcohol
use.4 Therefore it is important that the vaccine be extended to both male and female genders,
offering HPV cancer prophylaxis and prevention to both sexes. Extending the vaccine to both
males and females can help to decrease transmission of the HPV virus regardless of one’s gender
or sexual preference.
Gardisil is a quadrivalent 3 dose regimen vaccine that protects against HPV types 6, 11,
16, and 18. It has been proven to be highly protective and effective when given to females.
Gardisil was FDA approved for the male gender in 2009, after studies showed proven
effectiveness and immunogenicity in the male gender. Another HPV vaccine on the market is
under the name of Cervarix. This is a bivalent vaccine offering protection against HPV types 16,
and 18. At this time Cervarix is only FDA approved and indicated for the female gender. The
highest risk of acquiring HPV infection is within the first 5 years after sexual debut, and because
of this, the HPV prophylactic vaccination against would have the greatest benefit in sexually
naïve adolescents.3 The quadrivalent vaccine is however now approved and indicated for males
and females 9-26 years of age, regardless of their sexual preference or number of sexual partners.
Objective
The objective of this systematic review is to determine whether “It is safe and effective to
vaccinate the male gender to prevent HPV related neoplastic disorders in both the male and
female genders?” Recent approval of Gardisil does indicate safety and efficacy in boys and men
9 through 26 years of age for the prevention of genital warts (condyloma acuminata) caused by
HPV types 6 and 11. The FDA did not indicate the use of Gardisil in the male gender to help
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protect or prevent the transmission of HPV types 16, and 18.
Methods
A detailed search was completed by the author of this review using the advanced search
engine of PubMed, Ovid, Cochrane database of Randomized Control Trials, and Cochrane
database of Systematic Reviews. Key words in this research search were: Boys, Gardisil, HPV,
and HPV Vaccine and Males. This combination search was done and limits were placed for
published articles written in the English language from the time period of 2000 to 2009. The
criteria used for the selection of studies focused on the male population ages 9 to 26.
Administration of the HPV vaccine was the intervention; compared to those who received a
placebo vaccine, or injection of saline. Articles that were selected were based on Patient
Oriented Evidence that Matters (POEM). Outcomes were based upon the safety and tolerability
of the vaccine as measured by the patient, and whether or not the vaccine would prevent the
patient from having cancerous or neoplastic HPV (patient oriented evidence that matters).
Clinically, titers were drawn to prove the level of immunogenicity that the males would retain by
receiving the HPV vaccine, and also proving that males were non-inferior to females with
immunogenicity to the quadrivalent or bivalent HPV vaccine. The actual numeric value of the
titer levels are not considered POEM based because the antibody response is not something that
the patient cares about; however, it is the method clinically that researchers can use to prove
immunogenic response. Out of the three studies that were included; one was a comparative
study and the other two were randomized controlled trials. Two of the studies were double
blinded and the third study was observer blinded. The results of these demographics are
displayed in Table 1 along with the description of inclusion and exclusion criteria for the
individual studies. All three studies focused on the safety and efficacy of either the bivalent or
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quadrivalent vaccine within the male population. Table 1
Study

Type

# of
Pt’s

Age in
Years

Inclusion
Criteria

Exclusion
Criteria

W/D

Interventions

Block
2006

Comparative
Study
Randomized
DoubleBlinded

1,529

10-15
Male
and
female

Healthy boys
and girls that
were sexually
naïve before
and during the
study. For the
older
population of
females only,
they were
required to be
generally
healthy, have
an intact uterus,
with no
evidence of
cervicitis.

Allergy to any
vaccine
component; if
they had recvd
blood or
components
within the past 6
mos.; had any
known immune
or coagulation
disorder; had
recvd any
vaccine product
within 14 days
before
enrollment or
any live vaccine
product 21 days
before
enrollment. The
older females
aged 16-23 were
excluded if they
had HX of
genital warts,
abnormal pap,
HX of CIN, or >
4 lifetime sexual
partners.
Similar to that
described for a
non-inferiority
immunogenicity
bridging study. 3
Use of an
investigational
drug or vaccine
within 30 days;
use of immune
modifying drugs
within 6 mos;
blood or
products within 3
mos; previous
vaccine of HBV
or HPV;
active/past HBV
infection; HIV.

2

Quadrivalent
HPV vaccine
6/11/16/18;
this was
administered
to both male
and female
populations to
compare
immune
response.

6

Quadrivalent
HPV vaccine
6/11/16/18; vs.
saline placebo.

8

HPV 16/18
AS04adjuvanted
vaccine vs. the
HBV control
vaccine.

16-23
Female
Only

Reisinger
2007

RCT
Observer
Blinded

1,781

9-15

Healthy boys and
girls that were
sexually naïve
going into the
study.

Petaja
2009

RCT
DoubleBlinded

270

10-18

Healthy boys.
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Outcomes Measured
All 3 studies maintained a congruent approach to measure the safety and tolerability of
the vaccine. The participants were observed for at least 30 minutes after each vaccination for
any immediate reaction. Oral temperatures were recorded for 5 days following each injection.
The method that participants used to track their local or systemic adverse advents (AEs) is
known as a vaccination report card (VRC). Adult participants maintained a VRC themselves
post vaccination; and the VRC for adolescent participants were tracked by their parent/guardian.
Participants were given a scale and asked to rate their symptoms based upon mild, moderate, or
severe. “Mild” was defined as awareness of signs or symptoms, but easily tolerated; “moderate”
was defined by discomfort enough to cause interference with usual activities; and “severe” was
incapacitating with the inability to work or do usual activities (Block).1
The other outcome measured regarding a POEM based patient perspective is, do those
patients now have the protection from receiving or transmitting HPV related neoplasms?
Although the titer levels do show immunity, that is not something that a patient can gauge from
his or her perspective. However, the patient can gauge whether or not they have or can transmit
cancerous growths to their anogenital region.

Results: Tables 2-7 to include all three separate studies.
Table 2 and Table 3 Study on Comparison of the immunogenicity and Reactogenicity of
Prophylactic Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in
Male and Female Adolescents and Young Adult Women.
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Table 2: Safety Across all 3 series of vaccinations
Girls
Boys
Women
n/%
n/%
n/%
Participants 501
500
497
follow-up
Vaccine
423/84.4 396/79.2 444/89.3
AEs
Injection
405/80.8 370/74.0 435/87.5
site AEs
Systemic
154/30.7 136/27.2 160/32.2
AEs
Serious
1/0.2
1/0.2
0/0.0
AEs
Table 3: Efficacy; Non-inferiority of GMTs in Girls and Boys Vs Women at Month 7
Girls
Boys
Women
GMT Ratio
GMT Ratio
(95% CI)

Assay
(cLIA)
AntiHPV6
AntiHPV11
AntiHPV16
AntiHPV18
a
b

n/GMTa
n/GMTa
(mMU/ml) (mMU/ml)
423/959
428/1042

n/GMTa
(mMU/ml)
320/575

423/1220

428/1318

320/706

424/4697

427/5638

306/2548

426/916

429/1212

340/453

(95% CI)

Girls/Women

Boys/Women

1.67b (1.461.91)
1.73b (1.502.00)
1.84b (1.542.20)
2.02b (1.712.39)

1.81b (1.582.08)
1.87b (1.602.17)
2.21b (1.842.66)
2.68b (2.243.19)

Based on a statistical model adjusting for region.
Noninferiority P< .001

Table 4 and Table 5 is the Immunogenicity and Safety of HPV 16/18 AS04-Adjuvanted Vaccine
in Healthy Boys Aged 10-18 Years
Table 4 Safety and Tolerability of the HPV vaccine vs. Placebo
HPV 16/18
HBV N=259
N=523
Control
Symptom Type
n (%)
(95% CI)
n (%)
(95% CI)
378 (72.3)
(68.2, 76.1)
57 (22.0)
(17.1, 27.6)
Pain
All
a
10 (1.9)
(0.9, 3.5)
0 (0.0)
(0.0, 1.4)
Grade3
87 (16.6)
(13.5, 20.1)
29 (11.2)
(7.6, 15.7)
Redness
All
0 (0.0)
(0.0, 0.7)
0 (0.0)
(0.0, 1.4)
>50mm
56 (10.7)
(8.2, 13.7)
8 (3.1)
(1.3, 6.0)
Swelling All
2 (0.4)
(0.0, 1.4)
1 (0.4)
(0.0, 2.1)
>50mm
N= number of documented doses (with safety diary cards returned)
CI= exact confidence interval; n (%) = number/percentage of doses that were followed by at least one symptom.
a
Pain that prevented normal activity.
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Table 5 Immunogenicity Table2; GMT’s for HPV 16 and 18 antibodies in initially
seronegative boys aged 10 to 18 years at month 2 and month 7
14000
12000
10000
8000

HPV 16 at month 2

6000

HPV 16 at month 7

4000

HPV 18 at month 2

2000

HPV 18 at month 7

0
HPV16; n= 165/163 HPV 18; n=
152/150

Table 6 and 7 study on the Safety and Persistent Immunogenicity of the Quadrivalent
Vaccine in Preadolescents and Adolescents
Table 6 Safety and Adverse Experience Summary Across all 3 series of vaccines
Vaccine
Non-aluminum Placebo
1165
584
# of subjects w/ Follow-up
963 (82.7)
392 (67.1)
1 or more AE
877 (75.3)
292 (50.0)
Injection-site AE
237 (20.3)
77 (13.2)
Erythema
853 (73.2)
265 (45.4)
Pain
241 (20.7)
45 (7.7)
Swelling
541 (46.4)
260 (44.5)
Systemic AE
5 (0.4)
0 (0.0)
With serious AE
579
Fever; total number affected 1157
1074 (92.8)
541 (93.4)
<100 degrees F or normal
83 (7.2)
38 (6.6)
≥100 degrees F
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Table 7 Analysis of Month 7 Anti-HPV Responses for HPV Types 6/11/16/18
Parameter

Boys

Girls

Difference/Fold Difference

(95% CI)*
n
Response
n
Response
456
99.8
492
99.8
0.0 (-1.0, 1.0)
Anti-HPV 6
%Seroconversion
1007
808
1.3 (1.0, 1.5)
GMT
(mMU/mL)
457
99.8
492
99.8
0.0 (-1.0, 1.0)
Anti-HPV 11
%Seroconversion
1334
1187
1.1 (0.9, 1.4)
GMT
(mMU/mL)
455
99.5
489
99.8
-0.2 (-1.4, 0.8)
Anti-HPV 16
%Seroconversion
6316
4490
1.4 (1.1, 1.8)
GMT
(mMU/mL)
458
99.8
494
99.6
0.2 (-0.8, 1.3)
Anti-HPV 18
%Seroconversion
1581
1071
1.5 (1.2, 1.9)
GMT
(mMU/mL)
*Difference = Boys minus girls; Fold difference = boys divided by girls. P < 0.001 for all tests
of noninferiority of immune response in boys to those in girls (for all 4 vaccine HPV types for
both endpoints).

Results
The main point out of these three studies is to hypothesize whether or not it is safe and
effective to vaccinate the male gender with a HPV vaccine. In Table 2 and Table 3, the Block
study shows a comparison of immune response as well as safety of the vaccine in adolescents as
compared to women ages 16-23. The table provided includes all of the three groups of
participants and averages the outcome of tolerability and safety. The 3 dose regimen of the HPV
vaccine was overall well tolerated. The most commonly reported systemic adverse events were
headache (23.2%) and fever (13.1%).1 The majority of the injection site reactions
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were mild to moderate, characterized by redness and swelling. The first dose of the three dose
regimen was reported to carry the most complaints for redness and swelling. There were three
serious adverse events, 2 of them were proved to be unrelated to the vaccine; a cardiac
ventricular arrhythmia, and the second serious AE was an intentional overdose on
chlorpheniramine tablets and homeopathic arsenicum. The third serious AE was deemed to be
vaccine related by the reporting Physician; this participant was a 13 year old girl affected with a
vaginal hemorrhage 26 days post-dose 2 of the HPV vaccine.
Table 3 shows that the male population was non-inferior to immunogenicity of the girls
and woman at the 7th month; titers drawn 4 weeks after the 3rd dose of the vaccination regimen.
The end points of the study were the geometric mean titers (GMTs) of neutralizing antibodies for
each HPV type.1 The sample size of the study was chosen to provide >99% power to declare
noninferiority in immunogenic responses and seroconversion rates for at least 1 of the
populations (girls or boys compared with women) (Block).1 Therefore, turning this data into
POEM data, males are just as protected as females are from HPV after receiving the HPV
vaccine.
Table 4, Table 5, Table 6, and Table 7 show the same type of information as described in
Table 2 and Table 3. Table 4 does show that there were more AE’s of local and systemic
reactions with the HPV and compared to the placebo HBV vaccine. The Petaja study does
mention however that the solicited local symptoms did not affect compliance with the
vaccination, as evidenced by 97% of the boys in both vaccine groups completed the three dose
vaccination course.2 As shown in Table 5, the immune response in boys aged 10 to 18 years in
this study was noninferior for both seroconversion rates and GMTs to that seen in women aged
15 to 25 years in the historic comparator study, an age range in which a high
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degree of protection against HPV 16/18 infection and associated cervical lesions has been shown
(Petaja).2 Again, POEM based data is that males are as protected as females after receiving the
vaccine.
Tables 6 and 7 are much like that of the study of Tables 2 and 3. It is mentioned in the study
that 5 serious adverse events were reported through month 18, all of which occurred among the
quadrivalent HPV vaccine recipients, and were judged by the investigator to be not vaccine
related. As in the previous study, infection site adverse experiences were greater than placebo
but few participants discontinued the vaccination series because of the AEs. Table 7 shows that
for each of the 4 vaccine types, ≥99.5% of the subjects in the respective per-protocol
immunogenicity cohort had seroconverted by 1 month after completion of the 3-dose regimen,
regardless of their gender (Reisinger).3
Discussion
The two RCTs and one comparative study showed overall that the quadrivalent and the
bivalent HPV vaccine was safe and effective in preventing HPV and HPV related neoplasms.
There were adverse events that occurred within the HPV population greater than that within the
placebo, however, most of the events were consistent with local injection site redness and
soreness, and systemic reactions of either headache or fever. Most of these adverse events were
tolerated and discontinuance due to AEs of the vaccine regimen was a rarity. Immunogenicity of
the said HPV strains was proved by titer levels.
Conclusion
The antibody response of the HPV vaccine was shown to be noninferior to the studies
done in girls and women. The HPV vaccine was also proved to be overall safe with few minor
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immediate local and systemic side effects. Statistically, studies have shown that the first 5 years
following sexual debut represents the period of highest risk for acquisition of HPV infection.3
Therefore, immunizing males and females before their sexual debut becomes important to
prevent receiving and transmitting HPV. Thus stating, the vaccine should be targeted towards
adolescents and preteens. As mentioned in the introduction, an estimated annual cost for HPV
related neoplasms in the year 2000 for ages 15-24 was $2.8 billion for women, and $62 million
for men.5 It can only be assumed that in the year 2010, the incidence has increased. Given those
statistics, it is clear that HPV affects and takes lives of many individuals. HPV infection is
common in men and is readily transmitted influencing disease rates in both men and woman
(Petaja).2 The findings of safety and immunogenicity of the HPV vaccine in the male population
definitely lend support to the implementation of a gender neutral vaccine to prevent widespread
morbidity and mortality from HPV related cancers, as well as dysplastic cervical and external
genital lesions affecting the general population. The limitations to this study include long term
immune response which would necessitate the need for a booster vaccine.
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